A pivotal Phase 3 clinical trial of MO-03 in combination with standard immuno-oncology (IO) regimens for advanced and metastatic renal cell carcinoma
Latest Information Update: 20 Jan 2026
At a glance
- Drugs Clostridium butyricum M588 (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms BIOFRONT
- Sponsors Osel Inc
Most Recent Events
- 20 Jan 2026 New trial record
- 08 Jan 2026 According to Osel media release, company announced a clinical trial agreement with SWOG Cancer Research Network for a pivotal Phase 3 clinical trial of its lead oncology candidate, MO-03, in combination with standard immuno-oncology (IO) regimens for advanced and metastatic renal cell carcinoma (mRCC).
- 08 Jan 2026 According to Osel media release, the trial is slated for Q1 2026.